Inactive Instrument

SL Therapeutics, Inc. Stock

A258540

KR7258540004

Latest news : SL Therapeutics, Inc.

14/10/22	StemLab Inc. announced that it has received KRW 1.5000006 billion in funding	CI
28/07/22	StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding	CI
04/03/21	StemLab Inc. announced that it has received KRW 4 billion in funding	CI
24/02/21	StemLab Inc. announced that it expects to receive KRW 4 billion in funding	CI
27/10/20	StemLab Inc. announced that it has received KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd.	CI
21/06/19	StemLab Inc. announced that it expects to receive KRW 5 billion in funding from DAYLI Partners Co., Ltd., IBK Capital Corporation, Blueotus Co., Ltd., DB Asset Management Co., Ltd. and another investor	CI
29/03/19	StemLab Inc. announced that it has received KRW 1.5 billion in funding	CI
14/03/19	StemLab Inc. announced that it expects to receive KRW 1.5 billion in funding	CI

More news

Press Releases: SL Therapeutics, Inc.

25/02/23

In volo con Leonardo: the new work orientation pathway of the STEMLab project

More press releases

Managers and Directors: SL Therapeutics, Inc.

Manager	Title	Age	Since
Jong-Seong Choi CEO	Chief Executive Officer	62	19/10/2022
Seung-Kwon Yoo PSD	President	61	29/03/2021
Jung-Il No AUD	Comptroller/Controller/Auditor	65	12/08/2024

Director	Title	Age	Since
Jong-Seong Choi BRD	Director/Board Member	62	-
Hwang-Rae Kim BRD	Director/Board Member	63	29/03/2023
Seung-Kwon Yoo BRD	Director/Board Member	61	-

More insiders

SL Therapeutics Inc, formerly Stem Lab Inc, is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company is principally engaged in the development, research, manufacture and sale of biopharmaceuticals such as stem cell culture mediums, stem cell treatment as well as others.

Employees

Sector

Pharmaceuticals

More about the company

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SL THERAPEUTICS, INC.	+61.97%	+49.35%	-	-	403K
REGENERON PHARMACEUTICALS, INC.	+2.84%	+3.71%	+17.42%	-10.43%	63.56B
UCB	+2.60%	+3.12%	+58.73%	+232.75%	55.92B
SAMSUNG BIOLOGICS CO.,LTD.	+0.72%	+40.60%	+40.60%	+40.60%	41.68B
CSL LIMITED	-0.52%	+2.40%	-50.58%	-57.55%	39.12B
BIOGEN INC.	+3.26%	+7.91%	+63.62%	-23.65%	30.97B
MODERNA, INC.	+8.39%	+30.51%	+157.53%	-35.94%	28.77B
INCYTE CORPORATION	+2.95%	+9.17%	+72.20%	+89.09%	22.74B
INNOVENT BIOLOGICS, INC.	+7.22%	+9.49%	+8.86%	+188.34%	17.64B
SWEDISH ORPHAN BIOVITRUM AB	+2.43%	+2.04%	+68.04%	+130.36%	16.66B
Average	+9.13%	+5.12%	+48.49%	+61.51%	35.23B
Weighted average by Cap.	+2.84%	+4.34%	+42.70%	+55.34%

SL Therapeutics, Inc. Stock

Stocks

A258540

KR7258540004

Pharmaceuticals

Latest news : SL Therapeutics, Inc.

Press Releases: SL Therapeutics, Inc.

Quotes and Performance

Managers and Directors: SL Therapeutics, Inc.

Biopharmaceuticals

Company Profile